The Honest Guide to Larazotide: What Patients and Doctors Actually Say

Larazotide at a glance:

• Drug class: Tight-junction regulator peptide
• Manufacturer: 9 Meters Biopharma
• Route: oral capsule
• Typical frequency: before meals
• Half-life: minutes (acts locally in the gut)

Let's cut through the marketing on Larazotide and look at what the data actually say. Larazotide acetate is an oral peptide that inhibits zonulin, a regulator of intestinal tight junctions, with the goal of reducing paracellular permeability in celiac disease, and the result for users is: reduce gluten-induced symptoms in celiac patients on a gluten-free diet — though phase 3 (cedlara) did not meet its primary endpoint.

What is Larazotide?

Larazotide acetate is an oral peptide that inhibits zonulin, a regulator of intestinal tight junctions, with the goal of reducing paracellular permeability in celiac disease.

Larazotide is manufactured by 9 Meters Biopharma. Larazotide is not currently approved by the FDA for general human use. Available evidence comes from ongoing clinical trials. We do not endorse self-administration of unapproved compounds.

The drug class tight-junction regulator peptide works by targeting specific receptor pathways. Here's how that breaks down.

How Larazotide Works in the Body

Larazotide acetate is an oral peptide that inhibits zonulin, a regulator of intestinal tight junctions, with the goal of reducing paracellular permeability in celiac disease. The receptor target — compound-specific — drives the downstream effects users care about: reduce gluten-induced symptoms in celiac patients on a gluten-free diet — though phase 3 (cedlara) did not meet its primary endpoint.

The pharmacokinetics matter for daily use. Larazotide has a half-life of minutes (acts locally in the gut), which determines how often it is dosed. The standard route of administration is oral capsule, and the typical schedule is before meals.

For more detail on the underlying biology, see our breakdown of how Larazotide works.

Who Uses Larazotide?

Larazotide is most relevant for people whose situation maps to its approved indications: none — phase 3 trial in celiac disease did not meet primary endpoint.

People who should avoid Larazotide include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of Larazotide include:

• headache
• upper respiratory symptoms

Serious risks — uncommon but worth knowing — include:

• limited

We have a more detailed breakdown in our Larazotide side-effects guide.

Larazotide vs Alternatives

Strict gluten-free diet remains the standard for celiac disease. If you are weighing Larazotide against another option, our comparison pages include What Nobody Tells You About Larazotide Side Effects, What Is BPC-157? Everything You Should Know Before Starting, Is BPC-157 Safe? An Honest Look at the Side-Effect Profile.

Bottom Line

If you're considering Larazotide, the most useful next step is usually a conversation with a clinician who knows the full landscape of options — not just the one they prescribe most often. Phase 2 and 3 data show meaningful benefit, with phase 3 confirmation pending in some cases. If you are considering Larazotide, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• What Nobody Tells You About Larazotide Side Effects
• What Is BPC-157? Everything You Should Know Before Starting
• Is BPC-157 Safe? An Honest Look at the Side-Effect Profile
• BPC-157 Results: What the Real Numbers Show in 2026
• How Much Does BPC-157 Really Cost? The Honest Breakdown
• BPC-157 Cycle and Protocol: What Researchers Actually Use

Sources

• Sosne G et al. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy. Expert Opinion 2015;15:663.
• Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — Major Wound-Healing Properties. Pharmaceuticals 2020;13:155.
• Goldstein AL et al. Thymosin β4: A Multi-Functional Regenerative Peptide. Annals NY Acad Sci 2012;1269:1.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.